Metra Biosystems invests in Cholestech:
This article was originally published in Clinica
Executive Summary
Metra Biosystems will develop and market a cassette for Cholestech's LDX system to assess bone resorption. Metra, which has also made a "small equity investment" in Cholestech, will use its Pyrilinks-D urine assay for the new cassette. Additional equity investments will be made on completion of development milestones. Cholestech will market the assay in the US and both companies will distribute it internationally. The agreement between the two companies also provides for additional Metra assays to be added to the Cholestech system.